Adverse reactions reported in excess (> 0.5%) of placebo and as more than an isolated case in patients receiving pioglitazone in double-blind studies in combination with a sulphonylurea, including glimepiride, are listed below as MedDRA preferred term by system organ class and absolute frequency.